Safety of sebelipase alfa for the treatment of lysosomal acid lipase deficiency.

Abstract excerpt

INTRODUCTION: Lysosomal acid lipase deficiency is an autosomal recessive progressive lysosomal storage disease that mainly affects the liver, intestine growth, and causes dyslipidemia. The disease presents as two major phenotypes: the severe early-onset and late-onset forms. Sebelipase alfa is a recombinant human enzyme-replacement therapy for lysosomal acid lipase deficiency, which has been approved for...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Phenotype
• Share to Sterol Esterase
• Share to Enzyme Replacement Therapy